Day One Biopharma HSR waiting period ends

Day One Biopharmaceuticals amended its Schedule 14D-9 to report that the premerger waiting period under the Hart‑Scott‑Rodino Act was terminated early by the FTC on April 7, 2026 at 1:37 p.m. Eastern Time.

Rhea-AI Filing Summary

Day One Biopharmaceuticals amended its Schedule 14D-9 to report that the premerger waiting period under the Hart‑Scott‑Rodino Act was terminated early by the FTC on April 7, 2026 at 1:37 p.m. Eastern Time. The company confirms the HSR condition to the cash tender offer at $21.50 per share has been satisfied; the Offer remains subject to the other conditions set forth in the Offer to Purchase.

Insights

Antitrust Counsel

HSR waiting period ended early; remaining closing conditions unchanged.

The FTC’s early termination on April 7, 2026 clears the HSR filing hurdle tied to the cash tender offer at $21.50 per share. This removes one regulatory timing constraint but does not waive other contractual conditions in the Merger Agreement.

Timing and consummation now depend on the Offer’s residual conditions listed in Section 15 of the Offer to Purchase; any remaining closing steps and shareholder tender levels will determine next actions.

Key Figures

HSR early termination: April 7, 2026 at 1:37 p.m. ET Offer Price: $21.50 per share Premerger filing date: March 26, 2026 +1 more

4 metrics

HSR early termination April 7, 2026 at 1:37 p.m. ET FTC granted early termination of the HSR waiting period

Offer Price $21.50 per share Purchase price in the cash tender offer dated March 26, 2026

Premerger filing date March 26, 2026 Date Parent and Day One filed HSR Premerger Notification and Report Forms

Merger Agreement date March 6, 2026 Date of the Agreement and Plan of Merger among Day One, Parent, Purchaser, and Servier

Key Terms

HSR Act, Premerger Notification and Report Forms, Offer to Purchase

3 terms

HSR Act regulatory

"early termination of the waiting period under the HSR Act"

The HSR Act (Hart‑Scott‑Rodino Antitrust Improvements Act) requires companies in the United States to notify federal regulators and observe a waiting period before completing certain large mergers or acquisitions so authorities can check for anti-competitive effects. For investors it matters because the review can delay or block deals, force changes such as selling assets, and alter the expected value or timing of a transaction—like needing a permit before finalizing a major home renovation.

Premerger Notification and Report Forms regulatory

"filed their respective Premerger Notification and Report Forms with the FTC"

Offer to Purchase transaction

"terms set forth in the Offer to Purchase, dated as of March 26, 2026"

An offer to purchase is a formal proposal from one party to buy a specific amount of shares or assets from another party at a set price. It matters to investors because it signals interest in acquiring ownership and can influence the value or control of a company. Think of it as someone putting forward a clear, serious offer to buy something they find valuable.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the FTC early termination mean for DAWN's takeover offer?

It means the HSR waiting period ended early on April 7, 2026, removing that statutory timing hurdle. Remaining closing conditions in the Offer to Purchase still apply, so the tender offer must satisfy those other requirements before completion.

What is the cash price per share in Servier's offer for DAWN?

The Offer Price is $21.50 per share in cash. That is the stated purchase price for each of Day One’s common shares under the Offer to Purchase dated March 26, 2026.

Does the Amendment change any other terms of the merger agreement?

No. The Amendment restates that the HSR waiting period condition has been satisfied; all other terms and conditions of the Agreement and Plan of Merger and the Offer to Purchase remain unchanged.

When were the HSR filings made for Day One and Servier?

Parent and Day One filed their Premerger Notification and Report Forms on March 26, 2026, per the Amendment. The FTC granted early termination on April 7, 2026 at 1:37 p.m. Eastern Time.

Who certified the accuracy of the Amendment for DAWN?

The Amendment is certified by Charles N. York II, M.B.A., Chief Operating Officer and Chief Financial Officer of Day One Biopharmaceuticals, Inc., under the signature block dated April 8, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/08/2026 - 06:00 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14D-9

(Rule 14d-101)

Solicitation/Recommendation Statement

under Section 14(d)(4) of the Securities Exchange Act of 1934

(Amendment No. 1)

Day One Biopharmaceuticals, Inc.

(Name of Subject Company)

Day One Biopharmaceuticals, Inc.

(Name of Person(s) Filing Statement)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

23954D 109

(CUSIP Number of Class of Securities)

Jeremy Bender

Chief Executive Officer and President

Day One Biopharmaceuticals, Inc.

1800 Sierra Point Parkway, Suite 200

Brisbane, CA 94005

Telephone: (650) 484-0899

(Name, address and telephone number of person authorized to receive notice and communications

on behalf of the persons filing statement)

With copies to:

Effie Toshav, Esq. Douglas N. Cogen, Esq. David K. Michaels, Esq. Robert A. Freedman, Esq. Julia Forbess, Esq. Fenwick & West LLP One Front Street, 33rd Floor San Francisco, CA 94111 (415) 875-2300 Charles N. York II Chief Operating Officer and Chief Financial Officer Day One Biopharmaceuticals, Inc. 1800 Sierra Point Parkway, Suite 200 Brisbane, CA 94005 (650) 484-0899

☐ Check the box below if the filing relates solely to preliminary communications made before the commencement of a tender offer.

This Amendment No. 1 (this “Amendment”) to Schedule 14D-9 amends and supplements the Solicitation/ Recommendation Statement on Schedule 14D-9 previously filed by Day One Biopharmaceuticals, Inc., a Delaware corporation (“Day One” or the “Company”) with the Securities and Exchange Commission (the “SEC”) on March 26, 2026 (the “Schedule 14D-9”), relating to the cash tender offer (the “Offer”) by Servier Detroit Inc. (“Purchaser”), a Delaware corporation and a direct wholly owned subsidiary of Servier Pharmaceuticals LLC, a Delaware limited liability company (“Parent”), which is an indirect wholly owned subsidiary of Servier S.A.S., a French société par actions simplifiée (“Servier” and together with Purchaser and Parent, the “Servier Parties”), to purchase all of the issued and outstanding shares of Day One’s common stock, par value $0.001 per share (“Shares”), at a purchase price of $21.50 per Share (the “Offer Price”), net to the seller in cash, without interest thereon, and less any applicable tax withholding, upon the terms and subject to the conditions set forth in the Offer to Purchase, dated as of March 26, 2026 (as may be amended or supplemented from time to time, the “Offer to Purchase”) and the related Letter of Transmittal (as may be amended or supplemented from time to time, the “Letter of Transmittal”), and pursuant to the Agreement and Plan of Merger, dated as of March 6, 2026 (as it may be amended from time to time, the “Merger Agreement,” and the transactions contemplated therein, the “Transactions”), by and among Day One, Parent, Purchaser, and Servier.

Except as otherwise set forth in this Amendment, the information set forth in the Schedule 14D-9 remains unchanged and is incorporated herein by reference to the extent relevant to the items in this Amendment. Capitalized terms used but not defined herein have the meanings ascribed to them in the Schedule 14D-9.

Item 8. Additional Information

The subsection of Item 8 of the Schedule 14D-9 entitled “Regulatory Approvals—U.S. Antitrust Compliance” is hereby amended as follows:

On page 51, the final full paragraph is amended and restated as follows (new language underlined; deleted language struck through):

Parent and Day One expect to filed their respective Premerger Notification and Report Forms with the FTC and Antitrust Division on March 26, 2026.

On April 7, 2026, the FTC granted a request for the early termination of the waiting period under the HSR Act, effective April 7, 2026 at 1:37 p.m., Eastern Time. Accordingly, the condition to the Offer requiring that the waiting period (or any extension thereof) applicable to the Offer under the HSR Act shall have expired or been terminated has been satisfied. The Offer continues to be subject to the remaining conditions set forth in Section 15 of the Offer to Purchase.

1

SIGNATURE

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Amendment No. 1 to Schedule 14D-9 is true, complete and correct.

				Day One Biopharmaceuticals, Inc.
Date: April 8, 2026				By:		/s/ Charles N. York II, M.B.A.
						Name: Charles N. York II, M.B.A.
						Title:  Chief Operating Officer and Chief Financial Officer